Spikevax and mNEXSPIKE 2026-2027 formulas approved

Sponsor: Moderna $MRNA
Drug: Spikevax, mNEXSPIKE
Indication: COVID-19 prevention

What this means

Spikevax and mNEXSPIKE are Moderna's updated mRNA vaccines designed to protect against COVID-19. The FDA has approved their new 2026-2027 formulas for use in preventing the disease. This annual update ensures the vaccines continue to match the most recently circulating virus strains.

Read original at drugs.com ↗

Background Drug-class context · Wikipedia

The Moderna COVID‑19 vaccine, sold under the brand name Spikevax among others, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA). Depending on the jurisdiction, it is authorized for use in humans aged six months, twelve years, or eighteen years and older. The Moderna COVID‑19 vaccine provides protection against COVID-19, which is caused by infection by the SARS-CoV-2 virus. A different version of the Moderna COVID-19 vaccine, sold under the brand name Mnexspike (mRNA-1283), was approved for medical use in the United States in May 2025, and in the European Union in February 2026.

Source: Wikipedia · CC BY-SA

Topic COVID-19 vaccine

Share LinkedIn X Bluesky